Drilldown: Medicines
Use the filters below to narrow your results.
generic:
7-Hydroxymitragynine (1) ·
Acetylfentanyl (1) ·
Alfentanil (1) ·
Butorphanol (1) ·
Carbamazepine (1) ·
Carfentanil (1) ·
Codeine (2) ·
Desomorphine (1) ·
Dextropropoxyphene (1) ·
Diacetylmorphine (1) ·
Dihydrocodeine (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Kratom (1) ·
Lamotrigine (1) ·
Levorphanol (1) ·
Meperidine (1) ·
Mitragynine (1) ·
Nalbuphine (1) ·
O-Desmethyltramadol (1) ·
Oxcarbazepine (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Remifentanil (1) ·
Sufentanil (1) ·
Tapentadol (1) ·
Thebaine (1) ·
Tianeptine (1) ·
Topiramate (1) ·
U-47700 (1)
brand:
None (12) ·
(multiple, generic dominant) (1) ·
Alfenta (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Duragesic (1) ·
Heroin (1) ·
Krokodil (1) ·
Lamictal (IR), Lamictal XR, Lamictal ODT (1) ·
Nubain (1) ·
Nucynta (1) ·
O-DSMT (1) ·
Opana (1) ·
Stablon (1) ·
Stadol (1) ·
Sufenta (1) ·
Talwin (1) ·
Tegretol (IR, XR, suspension), Carbatrol (ER), Equetro (ER for bipolar), Epitol (1) ·
Topamax (IR), Trokendi XR, Qudexy XR, Eprontia (oral solution); component of Qsymia (with phentermine) (1) ·
Trileptal (IR), Oxtellar XR (1) ·
Ultiva (1) ·
Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
None (4) ·
Active metabolite of tramadol; mu-opioid agonist (1) ·
Extremely potent mu-opioid receptor agonist (1) ·
Highly potent mu-opioid receptor agonist (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; fentanyl analogue (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Opioid receptor partial agonist/antagonist; toxic alkaloid (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (6) ·
Prodrug of morphine; mu-opioid receptor agonist (1) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Selective mu-opioid receptor agonist (1) ·
Ultra-short-acting mu-opioid agonist (1)
uses:
None (29) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) ·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"' (1) ·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"' (1)
starting dose:
None (30) ·
Adult monotherapy: 300 mg PO BID, titrate by 300 mg every 3 days. Pediatric: weight-based titration starting 8-10 mg/kg/day divided BID (1) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Migraine: 25 mg PO at bedtime, titrate by 25 mg weekly to target 100 mg/day divided BID. Seizures: 25-50 mg/day, titrate weekly to 200-400 mg/day divided BID (1) ·
Seizures: 200 mg PO BID, titrate by 200 mg/week to 800-1200 mg/day. Trigeminal neuralgia: 100-200 mg BID, titrate to 200-400 mg TID. Bipolar: 200 mg BID, titrate to 1600 mg/day (1)
preparations:
None (29) ·
IR tablets 150, 300, 600 mg; oral suspension 60 mg/mL; XR tablets 150, 300, 600 mg (Oxtellar) (1) ·
IR tablets 200 mg; chewable 100 mg; oral suspension 100 mg/5 mL; XR tablets 100, 200, 400 mg (Tegretol XR); ER capsules 100, 200, 300 mg (Carbatrol, Equetro) (1) ·
IR tablets 25, 100, 150, 200 mg; chewable dispersible tablets 2, 5, 25 mg; ODT 25, 50, 100, 200 mg; XR tablets 25, 50, 100, 200, 250, 300 mg (1) ·
IR tablets 25, 50, 100, 200 mg; sprinkle capsules 15, 25 mg; Trokendi XR capsules 25, 50, 100, 200 mg; Qudexy XR capsules; Eprontia oral solution 25 mg/mL (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (29) ·
1200 mg/day (adult seizures); 1600 mg/day (bipolar mania) (1) ·
1600 mg/day (theoretical seizure dosing); practical use 400 mg/day for seizures, 100-200 mg/day for migraine prophylaxis (1) ·
2400 mg/day (adult) (1) ·
360 mg/day (1) ·
400 mg/day (bipolar monotherapy); 700 mg/day (epilepsy with enzyme-inducing comedication) (1)
onset:
None (29) ·
30–60 min (PO) (1) ·
Anticonvulsant effect within days at therapeutic level; migraine prophylaxis effect emerges over 2-3 months (1) ·
Anticonvulsant effect within days at therapeutic plasma level (1) ·
Anticonvulsant effect within days; trigeminal neuralgia relief 24-72 hours; mood-stabilizing effect over weeks (1) ·
Antiepileptic effect within days at therapeutic level; mood-stabilizing effect emerges over weeks (1)
duration:
halflife:
None (29) ·
'''Autoinduction''': 25-65 hours initially, falling to 12-17 hours after 2-3 weeks of dosing as carbamazepine induces its own CYP3A4 metabolism. Major clinical implication: doses require re-titration after the autoinduction period'"`UNIQ--ref-0000001D-QINU`"' (1) ·
2.5–3 hours (1) ·
Oxcarbazepine 2 hours; '''10-monohydroxy active metabolite (MHD) ~9 hours''' (the agent that produces essentially all of the clinical effect)'"`UNIQ--ref-0000001A-QINU`"' (1) ·
~21 hours'"`UNIQ--ref-00000028-QINU`"' (1) ·
~25-33 hours alone; ~15 hours with enzyme inducers; '''≥60 hours with valproate''' (UGT inhibition)'"`UNIQ--ref-00000025-QINU`"' (1)
bioavailability:
pregnancy:
None (29) ·
'''Among the safest mood stabilizers in pregnancy''' with reassuring monotherapy registry data, in sharp contrast to valproate. Estrogen-containing contraceptives accelerate lamotrigine metabolism, requiring dose adjustments at start and stop of contraception'"`UNIQ--ref-00000027-QINU`"' (1) ·
'''Substantial teratogenic risk''' including cleft lip/palate, hypospadias, and growth restriction (pregnancy registry data clear); effective contraception and pre-pregnancy counseling are required in reproductive-age patients'"`UNIQ--ref-0000002A-QINU`"' (1) ·
'''Substantial teratogenic risk''' including neural tube defects, craniofacial malformations, cardiac defects, and growth restriction; folic acid supplementation and effective contraception are required in reproductive-age patients'"`UNIQ--ref-0000001F-QINU`"' (1) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Teratogenic signal less than carbamazepine but present; folate supplementation and effective contraception are appropriate in reproductive-age patients'"`UNIQ--ref-0000001C-QINU`"' (1)
legal:
None (29) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the FDA '''Boxed Warning for serious skin reactions''' including Stevens-Johnson syndrome and toxic epidermal necrolysis, with the risk concentrated in the first 2-8 weeks of therapy and elevated by rapid titration'"`UNIQ--ref-00000028-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-0000002B-QINU`"' (1)
Showing below up to 34 results in range #1 to #34.